Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 4,153 shares, a growth of 351.4% from the July 15th total of 920 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average daily volume of 1,093 shares, the days-to-cover ratio is currently 3.8 days.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Addex Therapeutics in a research report on Monday, July 6th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Addex Therapeutics Stock Performance

Shares of ADXN opened at $5.85 on Wednesday. Addex Therapeutics has a 1 year low of $5.04 and a 1 year high of $12.05. The company’s 50 day simple moving average is $6.02 and its 200 day simple moving average is $6.63. The company has a market capitalization of $7.21 million, a price-to-earnings ratio of -0.99 and a beta of 1.50.

About Addex Therapeutics

Addex Therapeutics SA is a clinical-stage biopharmaceutical company specializing in the discovery and development of small-molecule allosteric modulators for central nervous system disorders. Founded in 1999 and headquartered in Geneva, Switzerland, with a U.S. research presence in Cambridge, Massachusetts, the company focuses on targeting metabotropic glutamate (mGlu) receptors and GABAB receptors to address unmet medical needs in neurology and psychiatry.

The company’s lead candidate, dipraglurant (ADX48621), is an mGlu5 negative allosteric modulator in clinical development for levodopa-induced dyskinesia in Parkinson’s disease.